A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia

José Luis Marín-Rubio,* Rachel E. Peltier-Heap, Maria Emilia Dueñas, Tiaan Heunis, Abeer Dannoura, Joseph Inns, Jonathan Scott, A. John Simpson, Helen J. Blair, Olaf Heidenreich, James M. Allan, Jessica E. Watt, Mathew P. Martin, Barbara Saxty, and Matthias Trost*

Cite This: J. Med. Chem. 2022, 65, 12014−12030

ABSTRACT: Inflammatory responses are important in cancer, particularly in the context of monocyte-rich aggressive myeloid neoplasm. We developed a label-free cellular phenotypic drug discovery assay to identify anti-inflammatory drugs in human monocytes derived from acute myeloid leukemia (AML), by tracking several features ionizing from only 2500 cells using matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry. A proof-of-concept screen showed that the BCR-ABL inhibitor nilotinib, but not the structurally similar imatinib, blocks inflammatory responses. In order to identify the cellular (off-)targets of nilotinib, we performed thermal proteome profiling (TPP). Unlike imatinib, nilotinib and other later-generation BCR-ABL inhibitors bind to p38α and inhibit the p38α-MK2/3 signaling axis, which suppressed pro-inflammatory cytokine expression, cell adhesion, and innate immunity markers in activated monocytes derived from AML. Thus, our study provides a tool for the discovery of new anti-inflammatory drugs, which could contribute to the treatment of inflammation in myeloid neoplasms and other diseases.

INTRODUCTION

Monocyte-derived macrophages play important roles in both physiological and pathological processes. The activation of these cells during pathogen infection or other insults leads, in part, to the pathophysiology of inflammation. Monocytes can recognize various damage-associated molecular (DAMPs) and pathogen-associated molecular patterns (PAMPs) through specific receptors, such as Toll-like receptors (TLRs). Activation of these receptors leads to the production of cytokines, chemokines, and mediators that are involved in inflammation in myeloid leukemia. Several hematopoietic disorders, including lymphoproliferative disorders and myelodysplastic syndromes, which possess a high risk of transformation to leukemia, have been linked to aberrant TLR signaling. Moreover, TLR2 and TLR4 show significantly higher expression in the bone marrow of patients with myeloid leukemia. TLR activation leads to intracellular signaling cascades including the mitogen-activated kinase (MAPK) pathways, increasing the expression and secretion of inflammatory cytokines and chemokines including interleukins, interferons, and tumor necrosis factor alpha (TNF-α). A shared characteristic of many hematologic malignancies is the overproduction of inflammatory cytokines, particularly TNF-α and IL-6 in myeloid malignancies.

The discovery of drugs that prevent chronic or acute inflammation is a major goal of the pharmaceutical industry for the treatment of infectious diseases, autoimmune diseases, and cancer. The discovery and design of new compounds for inhibiting inflammation are typically achieved through high-throughput screening (HTS) approaches. As such, there is a growing need to develop physiological phenotypic HTS assays that can be used for monocytic cell lines and primary cells to accelerate the discovery of inhibitors. Mass spectrometry (MS)-based readouts in drug discovery have been largely dominated by instruments consisting of solid-phase extraction (SPE) coupled electrospray ionization (ESI; i.e., RapidFire) or surface-based MS techniques, such as matrix-assisted laser/desorption ionization (MALDI). MALDI time-of-flight
MALDI-TOF MS is a versatile, label-free technique that has the potential to accelerate HTS of promising drug candidates.\textsuperscript{14–16} MALDI-TOF MS is tolerant to a number of standard buffer components and has rapidly become popular in the field of HTS drug discovery due to its versatility, requiring very small sample quantities, and minimal sample clean-up.\textsuperscript{14,15,17–20} MS-based screening approaches offer the possibility to simultaneously track several molecules in a label-free manner and provide excellent high-quality signals with minimum noise, reproducibility, assay precision, and cost effectiveness when compared to fluorescence-based assays.

Furthermore, fluorescence and chemiluminescence methodologies in primary cells and other readouts, such as antibody-based assays, are very expensive, making full-deck screens of millions of compounds difficult.\textsuperscript{13,20–22} MALDI-TOF MS, similar to acoustic mist ionization mass spectrometry,\textsuperscript{23} requires little sample preparation, allows rapid screening, and has high specificity and sensitivity.\textsuperscript{13} Whole cell analyses or cellular assays for evaluating compound efficacy affecting a cellular phenotype present an interesting challenge for MALDI-TOF MS analysis as the system becomes inherently more complex. One of the attractive qualities of this type of

**Figure 1.** Identification of features associated with the monocyte inflammatory phenotype by MALDI-TOF MS. (A) Workflow of the MALDI-TOF MS assay: (1) AML cells were pre-treated with a drug for 1 h before adding a pro-inflammatory stimulus for 24 h. (2) Cells were frozen on dry ice, thawed, and (3) washed with 100 mM Tris–HCl buffer at 4 °C. (4) Cells were mixed with a matrix (10 mg/mL α-cyano-4-cinnamic acid in 50% acetonitrile, 0.1% trifluoroacetic acid). (5) Cells were analyzed in a rapifleX PharmaPulse MALDI TOF mass spectrometer. (6) In the ionization chamber, a laser is used to produce ions in the gas phase. These ions are separated according to their time-of-flight (TOF) in a field-free region. The smaller ions reach the detector first followed by the bigger ions, according to the \(m/z\) ratio. (7) The detector converts the received ions into electrical current which is amplified and digitized in \(m/z\) spectra. (B) Unsupervised PCA plot of LPS, Pam\(_2\)CSK\(_4\), Pam\(_3\)CSK\(_4\), and IFN-\(\gamma\)-treated cells showing separation of cells treated with bacterial ligands treated and resting monocytes. (C) Loading plot derived from PCA in panel (B) showing that \(m/z\) 4964 and 4632 contribute predominantly to the separation of the two clusters in component 1 and component 2. (D) Unsupervised heat map of the relative intensities of three biological replicates of THP-1 cells treated with 100 ng/mL LPS, Pam\(_2\)CSK\(_4\), Pam\(_3\)CSK\(_4\), 100 U/mL IFN-\(\gamma\), 1 \(\mu\)g/mL poly(I:C), and poly(A:U) for 24 h compared to resting cells. (E) Box plots of significantly changing intensities between resting and LPS-treated monocytes identified at \(m/z\) 4632 and 4964. (F) Relative quantitation from three biological replicates of THP-1 cells treated with 100 ng/mL LPS, Pam\(_2\)CSK\(_4\), Pam\(_3\)CSK\(_4\), and 100 U/mL IFN-\(\gamma\) for 24 h compared to resting cells. (G) Titration of LPS, Pam\(_2\)CSK\(_4\), Pam\(_3\)CSK\(_4\)-treated cells from 10–100 ng/mL of stimulus. Significant differences between two groups were determined by the Mann–Whitney U-test. The statistical significance of the comparisons with resting is indicated as follows: ns, not significant; ***, \(P \leq 0.001\); **, \(P \leq 0.01\); *, \(P \leq 0.05\). Error bars represent the standard deviation of three biological replicates.
assay for the pharmaceutical industry is that the cellular assays provide biologically relevant information about the physiology and general condition of a cell, such as cell viability and protein activity in a single cellular screen.

This simultaneous acquisition of information is known as multiplexing and is desirable in cellular assays, as it significantly increases the screening efficiency of the compound library.

In this study, we have developed a cellular MALDI-TOF MS assay that is highly reproducible, robust, and sensitive in different cell lines, with which we can identify two main signatures altered under different pro-inflammatory stimuli. Using this MALDI-TOF MS assay, we performed a blind screen of 96 compounds to assess their potential anti-inflammatory effects on human monocytes derived from acute myeloid leukemia (AML). We discovered that nilotinib, but not the structurally related imatinib, inhibits the pro-inflammatory phenotype. Using thermal proteome profiling (TPP) and whole proteome analyses, we identified direct targets and downstream regulation of nilotinib during inflammation events. Our data showed that nilotinib and

Figure 2. Nilotinib is a positive hit in a cellular MALDI-TOF MS drug discovery screen and inhibits inflammation in response to LPS. (A) Inhibition of the TLR2 and TLR4 signaling pathways. MRT68601 inhibits TBK1 (TANK-binding kinase-1), which blocks production of type I interferons (IFNs). NG-25 inhibits TAK1 (TGF-beta-activated kinase-1), which induces TNF-α and IL-6 production. BI2536 inhibits BET proteins (bromodomain and extra-terminal motif proteins), which are required for pro-inflammatory gene transcription. (B) TNF-α secretion of THP-1 cells treated in either vehicle control-treated (DMSO), 100 ng/mL LPS-treated, or pre-treated with 5 μM NG-25, BI2536 or 1 μM MRT68601 for 1 h before 100 ng/mL LPS treatment for up to 24 h measured by ELISA. (C) MALDI-TOF MS relative quantitation of the normalized ratio m/z 4964/4632 in THP-1 cells as treated in panel (B). (D) PCA of all features identified by the MALDI-TOF MS of experiment in panel (B) and 0.5 μM staurosorpin-treated cells serving as control for apoptotic cells. (E) Compound hit map of the mean of three biological replicates with a 40% effectiveness cutoff showing nilotinib and NG-25 as positive hits and imatinib as the negative hit (arrows). (F) MALDI-TOF MS relative quantitation of the normalized ratio m/z 4964/4632 in THP-1 cells in vehicle control-treated (DMSO), 100 ng/mL LPS-treated, or pre-treated with 5 μM nilotinib, imatinib, 1 μM dasatinib, bosutinib, or ponatinib for 1 h before 100 ng/mL LPS-treatment for up to 24 h. (G) TNF-α secretion of cells treated as in panel (F) measured by ELISA after 24 h. Significant differences between two groups were determined by a Mann–Whitney U-test. The statistical significance of the comparisons with LPS is indicated as follows: ns, not significant; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. Error bars represent the standard deviation of four biological replicates.
other second- and third-generation BCR-ABL inhibitors, but not imatinib, are capable of blocking the p38α MAPK signaling pathway, which abates monocyte activation and differentiation, reduces cytokine release, and prevents inflammation in AML.

### RESULTS

A Novel MALDI-TOF MS Cellular Assay to Characterize Inflammatory Phenotypes. Recently, high-throughput MALDI-TOF MS has been used successfully for in vitro assays of specific enzymes. Here, we tested if MALDI-TOF MS can be used for phenotypic assays to monitor inflammatory responses by identifying differences in the “fingerprint” of biomolecules ionized when whole cells are spotted onto the MALDI target (Figure 1A). As a proof of concept, we tested if we could distinguish phenotypes of THP-1 cells, a model of human monocytes derived from AML, upon stimulation with a number of pro-inflammatory stimuli, namely, LPS, Pam_CS KO, Pam_CS KO, polyinosinic-polycytidylic acid (poly(I:C)), and polyadenyl-5¢-polyuridylic acid (poly(A:U)), which activate TLR4, TLR2/6, TLR1/2, and TLR3, respectively, as well as interferon-γ (IFN-γ). Principal component analysis (PCA) of all biomolecules detected in the range of m/z 2000–20,000 showed clear separation of monocytes treated with TLR-agonists, while IFN-γ treatment did not separate from untreated, suggesting that the features are not dependent on interferon stimulation but rather are TLR-dependent (Figure 1B). A loading plot analysis of the PCA results identified the features at m/z 4632, 4964, and 6891 as the main drivers for the difference in the phenotypes (Figure 1C). The features at m/z 4632 and 6891 were significantly reduced, while m/z 4964 increased in LPS-stimulated cells (Figure 1D,E and Figure S1A). As the feature at m/z 6891 showed a greater variability between replicates, we selected the features m/z 4632 and 4964 for further analysis of the phenotypes. We confirmed that other TLR ligands such as Pam_CS KO and Pam_CS KO, which activate TLR2/6 and TLR1/2, respectively, also increase this ratio and in a dose-dependent manner, while interferon-gamma (IFN-γ), poly(I:C), and poly(A:U) did not affect it (Figure 1F,G and Figure S1A). Thus, the m/z 4632 feature was used as a resting phenotype biomarker, while feature m/z 4964 was used as an LPS-stimulated monocyte phenotype biomarker. Together, these results indicate that biomarkers identified by MALDI-TOF MS can be used to detect changes in the inflammatory phenotype downstream of TLRs in AML cells.

MALDI-TOF MS Cellular Assay Can Detect Inhibitors of Inflammation. Next, we used NG-25, a TAK1 inhibitor that blocks TNF-α production, B12536, a PLK1 inhibitor that has been shown to inhibit pro-inflammatory gene transcription due to inhibition of BET proteins, and MRT68601, a highly selective and potent TBK1 inhibitor that blocks production of type I interferons (IFNs), to test if pharmacological inhibition of these pathways can be detected in our assay (Figure 2A). As LPS provided the greatest response of all inflammatory stimuli (Figure 1F,G), this stimulus was used for further assays. THP-1 cells were pre-treated with the inhibitors for 1 h before LPS-stimulation. NG-25 and B12536 treatment, but not MRT68601, reduced TNF-α (Figure 2B), IL-6, and IL-1β secretion (Figure 2A,B). It has been published that MRT68601 suppresses the production of type I interferons but increases production of pro-inflammatory cytokines, which we could not confirm within our experiments. Comparably to the cytokine secretion, our MALDI-TOF MS assay showed that treatment with NG-25 or B12536 blocked the inflammatory phenotype and was indistinguishable to vehicle control cells not treated with LPS, while MRT68601-treated cells still showed an increased ratio at m/z 4964/4632, similar to LPS-treated cells (Figure 2C and Figure S1B). Moreover, using all biomolecule features, PCA analysis showed that treatment with NG-25 reverted the fingerprint back close to control (Figure 2D). To verify that this phenotype was not due to cell death, we performed a cell viability assay (Figure S1L) that confirmed that LPS treatment did not induce apoptosis. Furthermore, cells treated with 0.5 μM staurosporine for 24 h before analysis with our MALDI-TOF assay showed that apoptosis leads to a distinct cluster in the PCA compared to control or LPS-treated cells (Figure 2D), suggesting that this assay can be multiplexed to identify other phenotypes such as cell toxicity. This data shows that pharmacological intervention of inflammatory pathways can be detected by our assay and that NG-25 can be used as a positive control compound in a high-throughput screen.

Label-Free MALDI-TOF MS Identifies Nilotinib as an Anti-inflammatory Compound. Once the analytical workflow was established to identify an inflammatory phenotype in THP-1 cells, we evaluated the potential of the assay to discriminate positive and negative inhibitors of inflammation in a proof-of-concept blind screen of 96 compounds (Table S1). The assay showed very good sensitivity (z’ = ~0.8) and reproducibility (R2 > 0.8) (Figure S3A,B). Only two positive hits were observed when applying a cutoff of 40% to the ratio m/z 4964/4632, as previously determined for MALDI-TOF MS assays.20 Unblinding revealed that these compounds were NG-25 and nilotinib (Tasigna) (Figure 2E). Nilotinib is a BCR-ABL tyrosine kinase inhibitor and is a second-generation derivative of imatinib (Gleevec), which was also included in the panel screened. However, imatinib did not affect the phenotype of inflammatory monocytes, while nilotinib-treated monocytes did not display an LPS-induced inflammatory phenotype and showed no differences compared to nonactivated monocytes in the ratio of m/z 4964/4632 (Figure 2F and Figure S1B). Moreover, we tested by MALDI-TOF MS other tyrosine kinase inhibitors (TKIs) used in chronic myeloid leukemia (CML) patients, the second-generation TKI dasatinib, and the third-generation TKIs bosutinib and ponatinib, which all also reduced the ratio m/z 4964/4632 ratio and thus inflammatory responses (Figure 2F and Figure S1C) without affecting cell viability (Figure S1M).

In order to validate the MALDI-TOF MS results, we measured secreted TNF-α levels in THP-1 cells treated with each inhibitor. Nilotinib as well as treatments with the second- and third-generation TKIs reduced secretion levels of TNF-α, IL-6, and IL-1β, while imatinib did not affect TNF-α (Figure 2G), IL-6, and IL-1β levels (Figure S2C,D) upon LPS treatment. Both MALDI-TOF MS and TNF-α ELISA data provided a similar IC50 of approximately 400–500 nM for the inhibitory effect of nilotinib (Figure S3C,D). This data indicates that nilotinib and later-generation TKIs are able to block inflammatory responses downstream of TLR activation, while the structurally similar imatinib cannot.

Nilotinib Blocks the Inflammatory Response by Inhibiting the p38α MAPK Pathway. Nilotinib is known to inhibit BCR-ABL and other tyrosine kinases. A putative role of these kinases in inflammatory signaling downstream of TLRs is unknown. Moreover, the target involved in this particular function is likely a kinase and must be a specific
target for nilotinib since the treatment with imatinib did not result in the same phenotype. In order to identify the off-targets responsible for the nilotinib-specific anti-inflammatory phenotype, we performed thermal proteome profiling (TPP) by multiplexed quantitative mass spectrometry using tandem mass tags (TMT) (Figure 3A, Tables S2 and S3). This method is based on determining the changes in the thermal stability of proteins, which may be due to direct drug binding, drug-induced conformation changes, binding to other cellular components, or post-translational modifications such as phosphorylation.27,28,31,33,35,44 We pre-treated THP-1 cells for 1 h with nilotinib or imatinib before stimulation with LPS for 15 min. We reduced the LPS treatment to 15 min in order to avoid changes in protein abundance due to transcriptional responses to LPS activation. Overall, we identified 5565 proteins in our TPP analysis (Table S4 and Figure S4). Only seven proteins changed significantly in all four replicates in melting temperature between nilotinib and imatinib, as shown in Table S4. These proteins were further validated by western blotting and melting temperatures (Tm) were calculated. (B) Determination of the thermostability of p38α (MAPK14) and (C) MK3 (MAPKAPK3) at the indicated temperatures with 5 μM nilotinib or imatinib for one hour before 100 ng/mL LPS-treatment for up to 15 min by TPP analysis. Table insert shows melting temperature (Tm °C) and R². (D) Determination of the thermostability of p38α at the indicated temperatures in vehicle control (DMSO), 100 ng/mL LPS and pre-treated with 5 μM nilotinib or imatinib for 1 h before 100 ng/mL LPS-treatment for up to 15 min. GAPDH served as a loading control. (E) Quantification of thermostability of p38α western blots from four independent experiments. Table insert shows melting temperature (Tm °C) and R². Error bars represent the SEM of four biological replicates. A representative image of four replicates is shown. Relative mobilities of reference proteins (masses in kDa) are shown on the left of each blot.

Figure 3. Thermal proteome profiling (TPP) reveals stabilization of p38α and MK3 in nilotinib-treated compared to imatinib-treated cells. (A) Workflow of TPP: (1) AML cells were pre-treated with the drug for 1 h before adding LPS for 15 min. (2) Cells were split in 8 different tubes and heated for 3 min at a range of temperatures (40, 44, 48, 52, 56, 60, 64, and 68 °C). Cells were lysed by freeze-thawing, and precipitates were removed by ultracentrifugation. (3) Proteins in the supernatants were digested with trypsin, labeled with 16-plex tandem mass tags (TMT) and (4) mixed. TMT-labeled peptides were fractionated using high-performance liquid chromatography (HPLC). (5) Peptides were analyzed in an Orbitrap Fusion Lumos Tribid mass spectrometer. (6) TPP data analysis was performed using MaxQuant and the computing environment R. (7) To validate the results, target proteins were analyzed by western blotting and melting temperatures (Tm) were calculated. (B) Determination of the thermostability of p38α (MAPK14) and (C) MK3 (MAPKAPK3) at the indicated temperatures with 5 μM nilotinib or imatinib for one hour before 100 ng/mL LPS-treatment for up to 15 min by TPP analysis. Table insert shows melting temperature (Tm °C) and R². (D) Determination of the thermostability of p38α at the indicated temperatures in vehicle control (DMSO), 100 ng/mL LPS and pre-treated with 5 μM nilotinib or imatinib for 1 h before 100 ng/mL LPS-treatment for up to 15 min. GAPDH served as a loading control. (E) Quantification of thermostability of p38α western blots from four independent experiments. Table insert shows melting temperature (Tm °C) and R². Error bars represent the SEM of four biological replicates. A representative image of four replicates is shown. Relative mobilities of reference proteins (masses in kDa) are shown on the left of each blot.
Figure 4. Nilotinib inhibits p38α-MAPK-MK2/MK3 signaling axis. (A) MALDI-TOF MS relative quantitation of the ratio m/z 4964/4632 in THP-1 cells pre-treated with DMSO, 5 μM nilotinib, imatinib, 1 μM losmapimod, or 1 μM MRT68601 for 1 h before stimulation with live E. coli for up to 24 h. (B) Western blot analysis of the p38α MAPK pathway in THP-1 cells pre-treated with DMSO, 5 μM nilotinib, 5 μM imatinib, 1 μM losmapimod, or 1 μM MRT68601 for 1 h before stimulation with live E. coli for up to 15 min shows loss of p38 phosphorylation in response to nilotinib. Nilotinib and losmapimod, but not imatinib, block phosphorylation of the downstream MK2. A representative image with two biological replicates of four replicates is shown. Relative mobilities of reference proteins (masses in kDa) are shown on the left of each blot. Relative quantification is shown in Figure S6C. (C) TNF-α, (D) IL-6, and (E) IL-1β secretion was measured by ELISA at 24 h. The statistical significance of the comparisons with E. coli is indicated as follows: ns, not significant; **, P ≤ 0.01; *** P ≤ 0.001. (F) TNF-α and (G) IL-6 expressions were determined by RT-qPCR in nontransfected or transfected HEK293 cells with p38α WT or p38α M107T for 48 h and pre-treated with DMSO, 5 μM nilotinib, or imatinib for 1 h before stimulation with LPS for up to 24 h. The results were analyzed using the 2−ΔΔCT method and normalized using GAPDH and TBP as the reference genes and nontransfected DMSO sample as the reference sample. Statistical significance of the comparisons: LPS nontransfected is indicated as T; LPS transfected with p38α WT is indicated as T; LPS transfected with p38α M107T is indicated as S. Error bars represent the standard deviation of four biological replicates. The statistical significance of the comparisons between p38α WT and p38α M107T is indicated as follows: ns, not significant; **, P ≤ 0.01. Significant differences between two groups were determined by the Mann–Whitney U-test.

imatinib with a standard deviation below two degrees. For three of these proteins, we detected increased ΔT_m in nilotinib-treated samples. The strongest hit was p38α (MAPK14) with an increased ΔT_m of 6 °C in nilotinib-treated samples (Figure 3B). The closely related isoform p38γ (MAPK12) did not show significant differences (Figure S5A). Also, MAPK-activated protein kinase 3 (MK3), a downstream protein target of p38, showed an increased ΔT_m of 2.5 °C in nilotinib-treated samples (Figure 3C). The remainder of significant proteins are shown in Figure S5B–F.

To validate p38α as a target of nilotinib, we performed western blots of lysates from a cellular thermal shift assay. The thermal denaturation temperatures for p38α in DMSO and LPS-treated monocytes were 50.3 and 50.2 °C, respectively. In accordance with the TPP data, the thermal denaturation temperatures for p38α with nilotinib was 60.7 °C, while with imatinib, it was 50.8 °C (Figure 3D,E). Examination of the TPP data for the upstream mitogen-activated protein kinase kinase 3 (MKK3), MKK4, and MKK6 (Figure S5G, J) did not show any differences. We further performed a concentration compound range experiment at 56 °C to determine the amounts of nilotinib required to alter protein thermal stability of p38α. We found that nilotinib was able to stabilize p38α at an EC50 concentration of 4.6 μM (Figure S5K, L). Moreover, we found that nilotinib is also able to affect p38 stability without LPS (Figure S5M, N).

To further understand the effect of nilotinib in preventing the inflammatory response by TLR activation in human monocytes, we used Escherichia coli (E. coli) to stimulate and induce an inflammatory response in THP-1 cells. We used live E. coli rather than LPS to activate multiple inflammatory pathways and not only the pathways downstream of TLR4. Similar to LPS treatment, we were able to identify the inflammatory phenotype after exposure to E. coli for 24 h using the MALDI-TOF MS assay (Figures S1D and S6A). Moreover, we tested by MALDI-TOF MS the p38 inhibitor losmapimod (GW86553X), which was tested in two phase III clinical trials (ClinicalTrials.gov Identifier: NCT04511819 and
In these results, losmapimod reduced the pro-inflammatory phenotype as well as nilotinib, but not imatinib nor MRT68601 (Figure 4A, Figure S6B, and Figure S1E,F). We observed a reduction in p38α and MK2 phosphorylation in stimulated monocytes treated with nilotinib similar to the specific p38 inhibitor losmapimod (Figure 4B and Figure S6C,D). As nilotinib did not affect the upstream activity of MKK3, it is likely that nilotinib binds p38α directly.

In order to demonstrate that the suppressive effects of nilotinib on the pro-inflammatory phenotype were mediated by inhibition of the p38 MAPK pathway in THP-1 cells, we analyzed the cytokine production mediated by p38 MAPK. In contrast to imatinib, nilotinib significantly reduced TNF-α, IL-6, and IL-1β levels and expression in monocytes stimulated with E. coli (Figure 4C,E and Figure S7A−E). To further show that this effect was due to direct binding to p38α, we overexpressed p38α and the drug-resistant p38α T106M. We found that nilotinib was able to inhibit the effect of p38α but not of the drug-resistant p38α T106M (Figure 4F,G and Figure S7F). Moreover, we performed surface plasmon resonance (SPR) analysis to validate the interaction between p38α and the analyzed TKIs (Figure S8). We found that

Figure 5. Nilotinib inhibits cell adhesion and monocyte activation. (A) PCA plot of log 2-transformed LFQ intensities from THP-1 cells pre-treated with DMSO, 5 μM nilotinib, or imatinib for 1 h before stimulation with live E. coli for up to 24 h, showing distinct grouping of treatments. (B,C) Volcano plot of THP-1 cells treated with (B) nilotinib vs imatinib and (C) nilotinib vs E. coli, a cutoff of FDR <0.05, and a 1.5-fold change between conditions. (D) Expression levels of CD44, (E) CD11c, (F) CD14, (G) CD49α, and (H) CD54 on the cell surface were measured by flow cytometry. (I) Optical density of dissolved crystal violet was used to evaluate the adhesion rate. Significant differences between two groups were determined by the Mann–Whitney U-test. The statistical significance of the comparisons with E. coli is indicated as follows: ns, not significant; *, P ≤ 0.05; **, P ≤ 0.01. Error bars represent the standard deviation of four biological replicates.
nilotinib, ponatinib, and dasatinib bind directly to p38α and the affinity constant (K_D) for the interaction was in the low nanomolar range (Figure S8A−C), while bosutinib was in the micromolar range (Figure S8D). Moreover, nilotinib and ponatinib have slow off rates (K_off), which might extend the duration of the compound effect. Imatinib or MRT68601, however, did not bind to p38α (Figure S8E,F). The observed box-shaped sensorgram from the SPR data for bosutinib and imatinib indicates weak or transient protein-drug interactions (Figure S8D,E), as characterized by the rapid association upon sample injection, the steady equilibrium phase, and the rapid dissociation leading back to the buffer baseline. Altogether, our results indicate that nilotinib binds specifically to p38α, which inhibits its activity and affects the production of pro-inflammatory cytokines, thereby reducing inflammation.

**Nilotinib Prevents Monocyte Activation.** To better understand differences between nilotinib and imatinib treatments on monocytes, we performed quantitative proteomics of THP-1 cells pre-treated with DMSO, 5 μM nilotinib, imatinib, 1 μM dasatinib, bosutinib, ponatinib, or losmapimod for 1 h before stimulation with 100 ng/mL LPS for up to 24 h. (C,D) TNF-α secretion was measured by ELISA at 24 h in (C) human primary monocytes and (D) primary AML cells. Error bars represent the standard deviation of four or two biological replicates. Significant differences between two groups were determined by the Mann−Whitney U-test. The statistical significance of the comparisons with E. coli is indicated as follows: ns, not significant; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. (E) Effect of nilotinib during pro-inflammatory stimulation. Activation of TLR4 by a pro-inflammatory stimulus induces p38 MAPK signaling. Nilotinib inhibits p38 phosphorylation and MK2 phosphorylation, reducing the levels of cytokines such as TNF-α, IL-6 or IL-1β, and cell adhesion molecules (CAMs).
to differentiation into macrophages and also leads to an increased expression of cell adhesion proteins. To further understand how nilotinib affected activation of monocytes and their differentiation into macrophages upon stimulation with E. coli, we studied cell surface differentiation and cell adhesion markers. We validated our proteomics data by showing that MMP9 and CD44 upregulation induced by E. coli was abolished with nilotinib but not with imatinib (Figure S8C and Figure 5D). Furthermore, monocyte activation markers CD11c, CD14, CD49a (integrin α1), and CD54 (ICAM-1) were suppressed with nilotinib treatment but not with imatinib (Figure 5F,H). Also, we observed less cell adhesion with nilotinib treatment than with imatinib (Figure S1). These results indicate that nilotinib inhibits the inflammatory response of monocytes under a pro-inflammatory stimulus, inhibiting their differentiation into macrophages.

**Nilotinib Reduces the Inflammation Phenotype in AML.** Nilotinib is a second-line therapy for CML patients who failed or were intolerant to imatinib, but little is known about its use in other types of cancer. We performed an in silico analysis of data from the Genomics of Drug Sensitivity in Cancer (GDSC) database to explore the sensitivity of nilotinib and imatinib sensitivity in different cancer types including hematological and solid tumors. We found that the sensitivity to nilotinib was significantly higher than that to imatinib in hematological malignancies and gastrointestinal tumors (Figure S10A). Interestingly, AML, MM, and diffuse large B cell lymphomas (DLBCL) showed significant differences between the sensitivities to nilotinib and imatinib treatments (Figure S10B). These data support the interest of studying the effects of nilotinib and imatinib in myeloid malignancies as AML. In order to test whether our cellular MALDI-TOF assay can be performed in other cell lines than in THP-1 cells and to test whether nilotinib and other TKIs can be an effective treatment in other monocyte-rich aggressive myeloid neoplasms, we used another monocyte AML cell line, OCI-AML2, and the MM cell line, NCI-H929. We also observed a significant reduction in the ratio m/z 4964/4632 by MALDI-TOF MS in both hematopoietic cell lines treated with nilotinib (Figure S10C and Figure S1G,H). Furthermore, we confirmed that nilotinib inhibits p38 MAPK phosphorylation and subsequent MK2 phosphorylation in OCI-AML2 and NCI-H929 cell lines after exposure to E. coli (Figure S10D). Moreover, as we observed in THP-1 cells, TNF-α, IL-6, and IL-1β secretion were reduced with nilotinib treatment in OCI-AML2 (Figure S10E).

In addition, we performed our MALDI-TOF MS assay in peripheral blood primary human monocytes and primary patient AML cells. For this, we isolated primary human positive CD14 monocytes from four healthy donors and AML cells from two patients (#274 and #312). We also observed a significant reduction in the ratio m/z 4964/4632 by MALDI-TOF MS in both LPS-stimulated primary monocytes and AML samples treated with nilotinib as well as with the third-generation TKI, ponatinib, and the p38 inhibitor losmapimod (Figure 6A,B and Figure S11J), while ponatinib and bosutinib were more variable. Moreover, TNF-α secretion was reduced with nilotinib treatment in both LPS-stimulated primary monocytes and AML patient cells (Figure 6C,D). Taken together, these results show that our MALDI-TOF MS assay is a suitable tool to detect pro-inflammatory phenotypes via specific biomarkers (m/z 4632 and 4964) in AML and monocytes. Furthermore, our data show that nilotinib inhibits the p38α MAPK-MK2/MK3 signaling axis during the inflammatory response, reducing the levels of the pro-inflammatory cytokines in myeloma cells (Figure 6E).

**DISCUSSION**

Inflammation has an important role in many aspects of acute myeloid leukemia (AML) such as disease progression, chemoresistance, and myelosuppression. For the last five decades, AML treatment has been limited to intensive chemotherapy with cytarabine and anthracycline. Nonstandard chemotherapy or immunotherapy is indicated if certain mutations or markers are detected in cancerous cells. Recently, there have been major efforts to understand the disease on the molecular level and to develop novel drugs, including targeted therapies such as tyrosine kinase inhibitors (TKIs). To date, 89 drugs targeting protein kinases have been clinically approved by the Food and Drug Administration (FDA, April 2021), while at least 150 are being investigated in clinical trials. Development of new high-throughput phenotypic drug screening approaches is important for the identification of novel drugs for the treatment of inflammation in autoimmune diseases and cancer. However, current methods for measuring pro-inflammatory cytokines are expensive as they utilize antibodies, making “full deck” analyses of millions of compounds inaccessible. MALDI-TOF MS is a versatile technique with many different applications, ranging from protein identification by peptide mass fingerprinting and small molecule analysis to imaging of tissues. As the technology allows very fast screening, it has already found traction in the HTS field with its application to label-free screening of in vitro assays.

In this study, we present a cheap (Table S7), rapid, and label-free cellular MALDI-TOF MS assay able to identify an inflammatory phenotype in monocytic cells and to screen for anti-inflammatory drugs. We applied a screen to whole cells, allowing the identification of biomarkers that provide a specific fingerprint for the phenotype of the analyzed cells. Two features at m/z 4632 and 4964 were significantly altered upon different inflammatory stimuli, such as, LPS, Pam3CSK4, Pam2CSK4, and E. coli in the monocytic AML cell line THP-1. The feature m/z 4964 has been previously described as a biomarker to identify patients with Crohn’s Disease, intestinal tuberculosis, or rheumatoid arthritis using MALDI MS imaging. It has been associated with thymosin beta 4 (TB4), a small protein involved in binding and promoting actin polymerization; however, it has also been described as having anti-inflammatory properties. Since the protein is only 44 amino acids, TB4 was not identified in our TPP or proteomics data and an attempt to identify it by MS/MS directly from cells by MALDI-TOF MS failed; Fourier-transform ion cyclotron resonance mass spectrometry (FT-ICR MS) might allow the identification of these biomarkers. We showed that the cellular MALDI-TOF MS assay can determine the inflammatory phenotype upon activation of the plasma membrane Toll-like receptors (TLR), such as TLR1, TRL2, TLR4, and TLR6, but not upon activation of interferon receptors or the intracellular TLR3 receptor.

While we tested a range of different pro-inflammatory stimuli, we found the greatest response upon LPS stimulation, which was used in a proof-of-concept blind screen of 96 selected compounds. Within this screen, we identified nilotinib as a drug that prevents the inflammatory phenotype in stimulated AML cells by MALDI-TOF MS. However, the
structurally similar drug imatinib did not have this anti-inflammatory effect. Imatinib and nilotinib are BCR-ABL tyrosine kinase inhibitors (TKIs) and the standard first-line therapy for CML. However, nilotinib possesses higher potency than imatinib against BCR-ABL and is active against most imatinib-resistant BCR-ABL mutations. The second-generation TKIs, dasatinib and bosutinib, as well as the third-generation TKI, ponatinib, are also potent multivertargeted tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. These compounds have been previously suggested to have potential anti-inflammatory effects, which we confirmed in our data within a range of cell types.

Leukemic blasts often secrete inflammatory cytokines such as TNF-α, IL-1β, and IL-6, which induce expression of proteins necessary for their adhesion to the vascular endothelium, migration to tissues, proliferation, and chemoresistance. Stimulation with TLR ligands activates monocytes, which leads to the production of cytokines, chemokines, and mediators that are involved in inflammation. TLR ligation induces the formation of a signaling complex that includes IL-1R-associated kinases (IRAKs) and TNFR-associated factor 6 (TRAF6), which mediates the K63-linked polyubiquitylation and activation of TGF-β-activated kinase 1 (TAK1). TAK1 is a MAPK kinase kinase (MAP3K) upstream of p38 MAPK and Jun N-terminal kinases (JNKs). p38 MAPK directly phosphorylates other protein kinases termed MAPK-activated protein kinases (MKs). The MKs that are phosphorylated by and functionally subordinate to p38 MAPK include MK2 and MK3, which play a versatile role in transcriptional and translational regulation, and affect inflammatory responses, triggering the production of cytokines and chemokines.

Here, we performed a thermal proteome profiling analysis using TMTpro 16-plex, to identify the possible different targets between nilotinib and imatinib during the inflammatory response. Of the most significant and highly reproducible targets identified was p38α as a main off-target of nilotinib, when compared to imatinib. The direct binding of nilotinib, imatinib, dasatinib, and bosutinib to p38α was described before by an in vitro competition binding assay. While this technology is very powerful, TPP analyses detected that nilotinib affected p38α thermal stability but not imatinib. Nilotinib has been reported to inhibit p38α activity and p38β. Furthermore, we found MK3 as thermally stabilized by nilotinib, when compared to imatinib, although this could be down to changes in the phosphorylation status. However, we did not find any evidence for p38γ inhibition in our experiments, suggesting remarkable specificity for the p38α isoform. While the loss of p38 phosphorylation would suggest an inhibition upstream of p38 MAPK, we found that no differences for any MAPKK and MAPKKK-independent p38 phosphorylation have been described before. Furthermore, our results showed that nilotinib interferes with the downstream MAPK signaling pathway comparable to the specific p38 inhibitor, losmapimod (GW86553X), which has been studied in two phase III clinical trials. Moreover, we found reduction in the pro-inflammatory phenotype, in p38 phosphorylation, and in MK2 phosphorylation when dasatinib, bosutinib, and ponatinib were used. p38α has been described a common off-target for nilotinib, dasatinib, and other TKIs.

The potential of p38 MAPK inhibitors was initially explored within inflammatory conditions such as cancer, acute myocardial infarction, rheumatoid arthritis, and Crohn’s disease, but the studies demonstrated poor clinical efficacy and unacceptable side effects. This suggests that nilotinib may be considered for additional applications outside of cancer, particularly as it is well tolerated by patients and has few side effects. Within the cancer field, it appears that the anti-inflammatory off-target effects from nilotinib may be beneficial, as seen in tumors co-treated with doxorubicin and vincristine. Consistent with these results, nilotinib, but not imatinib, can reduce the inflammation in human monocytes derived from AML and other myeloid cells. Moreover, nilotinib and ponatinib had slow dissociation rates (Kd), which has been associated with better selectivity, lower toxicity, and a broader therapeutic window.

Dysregulation of TLR signaling has been linked with myeloproliferative disorders. While TLRs are specific for exogenous PAMPs such as lipopolysaccharide (LPS), which triggers TLR4 signaling in monocytes and macrophages, they are also activated by specific endogenous DAMPs such as HSP60 or biglycan. The bacterial surface molecule LPS activates TLR4 and CD14 in monocytes, inducing pro-inflammatory (IL-1, IL-6, and TNF-α) and then anti-inflammatory (IL-10, soluble TNF receptor, and IL-1 receptor antagonist) cytokines. Nilotinib treatment was able to decrease the levels of IL-1β, IL-6, and TNF-α cytokine secretion upon stimulation with E. coli in AML cells. In line with our results, pre-incubation with nilotinib in murine macrophages derived from bone marrow (BMDMs) led to a decreased LPS-induced IL-6 expression. Furthermore, monocyte differentiation into macrophages induces an upregulation of CD11c and CD14 surface markers, as well as cell adhesion molecules. Interestingly, nilotinib was able to block the upregulation of CD11c, CD14, CD44, CD49a, and CD54 markers, thus reducing immune response and cell adhesion of monocytes. We further found MMP9, which cleaves CD44 and induces cell migration and cell—cell and cell—matrix adhesion, downregulated upon nilotinib treatment. A potential mechanism of action is the nilotinib-dependent increase of ROCK1 levels in E. coli-stimulated cells, as deficiency in ROCK1 has been implicated in the migration and recruitment of inflammatory cells such as macrophages and neutrophils during acute inflammation. Furthermore, we observed a reduction in cell adhesion in activated monocytes upon nilotinib treatment, compared to imatinib. Our data therefore suggests that nilotinib may not only affect inflammatory signaling and immune cell adhesion but also differentiation from monocytes into macrophages.

Our study provides a valuable tool to discover new anti-inflammatory drugs using a cellular MALDI-TOF MS assay, as we demonstrate here for nilotinib. We show that nilotinib inhibits the p38α MAPK-MK2/3 signaling axis and prevents its phosphorylation and subsequent activation, ultimately preventing the transcription of pro-inflammatory genes, cell adhesion markers, and innate immunity markers. In consequence, nilotinib may have therapeutic potential through the inhibition of the p38 MAPK-MK2/3 axis in inflammatory diseases as well as in myeloid malignancies such as myeloid leukemia and multiple myeloma.

### METHODS

**Compounds.** LPS was purchased from Sigma-Aldrich; Pam3CSK4, Pam2CSK4, poly(A:U), and poly(I:C) from Invitrogen; mouse IFN-γ from PeproTech; MRT68601, bosutinib, dasatinib, and ponatinib from Tocris; losmapimod from Bio rotary; and nilotinib, imatinib, NG-
25, and the other compounds from Table S1 were provided by LifeArc. All compounds are >95% pure by HPLC analysis.

**Cell Culture.** Acute myeloid leukemia-derived cell lines THP-1 (ATCC) and OCI-AML2 (DSMZ), and multiple myeloma-derived cell lines NCI-H292 (ATCC) were cultured in RPMI 1640 medium (Gibco) supplemented with 10% FBS and 4 mM l-glutamine at 37 °C in a humidified 5% CO2 atmosphere. ATCC and DSMZ routinely perform cell line authentication, using short tandem repeat profiling as a procedure. Cell experimentation was always performed within a period not exceeding 6 months after resuscitation in mycoplasma-free culture conditions.

**Transient transfection with Lipofectamine.** HEK293 (ATCC) were transfected using the Lipofectamine LTX Reagent and OptiMEM Reduced Serum Medium (Thermo Fisher) with pCMV-MAPK14 (p38α) WT (DU1765) and pCMV-MAPK14 (p38α) T106M (DU3741) from MRC PPU, University of Dundee.

**Isolation of Human Monocytes from Peripheral Blood Mononuclear Cells (PBMCs).** Mononuclear cells were freshly isolated from peripheral blood collected from five healthy donor volunteers. Blood was collected into citrate buffer. PBMC were isolated using the Pan Monocyte Isolation Kit (Miltenyi Biotech) and cultured in RPMI medium supplemented with 10% FBS, 4 mM l-glutamine, and 50 μg/mL penicillin/streptomycin. The study was conducted according to the principles expressed in the Helsinki Declaration, and informed consent was obtained from all participants.

**AML Patient Cells.** AML sample cells were collected after informed consent was provided via the Newcastle Hematology Biobank (Ref: 12/NE/0395). The cells were cultured in Iscove’s modified Dulbecco’s medium supplemented with 20% FBS, 4 mM l-glutamine, 50 μg/mL penicillin/streptomycin, 10 ng/mL interleukin-3 (PeproTech), and 20 ng/mL stem cell factor (PeproTech). The study was conducted according to the principles expressed in the Helsinki Declaration, and informed consent was obtained from all participants.

**Quantitative RT-PCR.** RNA was extracted using TriZol (Thermo Fisher Scientific). Real-time RT-qPCR from total RNA in two steps was performed with a Quantitect reverse transcription kit (Qiagen) and a QuantiTect SYBR green kit (Qiagen) using a StepOne Applied Biosystems real-time PCR system (Thermo Fisher Scientific). Expression values of GAPDH and TBP genes in the same samples were used for normalization, using the 2ΔΔCT method. The following primers were used: GAPDH, forward: GTCTCCTCTGACCTCCAACAGG and reverse: ACCACCTCTTGTCTGTGAACCA; IL-6, forward: GCCCAGCTGAAGCTCTCTCT and reverse: CTTCTCCTGGGCGTACTGG; TBP, forward: GAGTTCCACGG-CIGNEDT and reverse: GGCGTCAGCTCAGTGCACA; TNF-α, forward: AAACCTGAGCAGTCTGCA and reverse: AGGAGATACTTCGGATCGCA and reverse: AGGAGATCTTCGATTTTGAGG.

**ELISA.** The cell culture supernatant was collected at 24 h post-treatment. TNF-α, IL-6, and IL-1β were measured by Duoset ELISA kits (R&D Systems). Absorbance from four biological replicates at 450 nm was measured with the correction wavelength set at 540 nm using a SpectraMax M3 microplate reader (Molecular Devices).

**Western Blot.** Cells were lysed using 5% SDS supplemented with the Protease Inhibitor Cocktail and Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich). The following antibodies were purchased from Cell Signaling Technology (Davies): MK2 (#3042), Thr-324-P-MK2 (#3041), MK3 (#7421), MKK3 (#8535), Ser189-P-MKK3/Ser207-P-MKK6 (#12280), p38 MAPK (#9212), p38α MAPK (#9218), p38γ MAPK (#2037), Thr180/Tyr182-P-p38 MAPK (#4511), MPP9 (#5635), and p44/42 MAPK (#4690). The following antibodies were purchased from Cell Signaling Technology (Davies): p38 MAPK (#9212), p38α MAPK (#9218), p38γ MAPK (#2037), Thr180/Tyr182-P-p38 MAPK (#4511, MPP9 (#5635), anti-rabbit IgG-HRP (#7074), and anti-mouse IgG (#7076). GAPDH (sc-77724) was from Santa Cruz, and α-tubulin (T9026) was from Sigma-Aldrich. The Amersham Imager 600 digital imaging system (GE Healthcare) was used for image acquisition.

**Flow Cytometry.** Cell surface staining was performed by the direct immunofluorescence assay with fluorescent-conjugated antibodies: CD11c-APC (#17-0114-82), CD14-AF700 (#86-0149-42), and CD54-FITC (#11-0541-82) from Thermo Fisher; CD49a-PE (#562115) and CD44-FITC (#338803) from BD Biosciences; and corresponding isotype control antibodies, for 30 min at 4 °C in PBS with 1% FBS, 1% BSA, and 1% human serum (Sigma) to block Fc receptors. Cells were analyzed in a FACSCount II flow cytometer (Becton-Dickinson). The results were analyzed using FlowJo.

**Adhesion Assay.** Cells were washed twice with PBS before being fixed with 4% paraformaldehyde for 15 min. Then, cells were incubated with 5 mg/mL crystal violet for 10 min before lysis with 2% SDS for 30 min. Absorbance from four biological replicates at 550 nm was measured using a SpectraMax M3 microplate reader (Molecular Devices).
Devices. Micrographs were acquired with an inverted microscope Axio Vert.A1 FL LED (Zeiss, Cambridge).

Surface Plasmon Resonance (SPR). SPR ligand interactions assays were performed on a Biacore S200 (Cytiva Life Sciences) at 2 °C using multicycle settings. Biotinylated avidin-p38⁰ IR (MRC-Reagents, Dundee) was immobilized onto a Streptavidin surface chip, through injection of 50 μg/mL p38⁰ in DMSO-free SPR running buffer (20 mM HEPES, 150 mM NaCl, 0.1 mM EGTA, 0.5 mM TCEP, 0.01% Tween-20, pH 7.4) over the active flow cell eliciting final captured response units (RU). The inhibitor analytes (20 mM HEPES, 150 mM NaCl, 0.1 mM EGTA, 0.5 mM TCEP, 0.01% Tween-20, pH 7.4, 1% DMSO) were then injected over both control- and test-surfaces for 30 s/min before being allowed to dissociate for 360 s (imatinib, dasatinib, bosutinib, and MRT68601) and 600 s (nilotinib, ponatinib) over 10 concentration series to record dose-responses: 0.05–333.33 nM for nilotinib and ponatinib, 0.51–10 μM for dasatinib and bosutinib, and 2.54–50 μM for imatinib and MRT68601. A solvent correction was applied to the data collection, and an 8-point DMSO solvent correction was applied. Responses were analyzed using Biacore Evaluation Software (Cytiva Life Sciences) using affinity fit to determine the IC₅₀. Data are representative of three technical replicates.

Cellular Thermal Shift Assay. Cells were treated with 5 μM nilotinib or imatinib for 1 h, and then 100 ng/mL LPS was added for 15 min. Cells were washed with PBS supplemented with cOmplete, EDTA-free Protease Inhibitor Cocktail (Sigma-Aldrich), 1.2 mM sodium selenite, 1 mM sodium orthovanadate, 4 mM sodium tartrate dihydrate, 5 mM glycerophosphate, and 20 mM N-ethylmaleimide, which were then separated into 8 fractions for thermal profiling. Fractions were heated at 40, 44, 48, 52, 56, 60, 64, and 68 °C for 3 min. For concentration compound range experiments, cells were treated with 0.1, 0.5, 1, 5, or 10 μM nilotinib or imatinib for 1 h before treatment with 100 ng/mL LPS for 15 min. Cells were heated at 56 °C for 3 min. Samples were lysed with four freeze–thaw cycles using dry ice and a thermoblock at 35 °C. Cell lysates were centrifuged at 4000g for 2 h at 4 °C to separate protein aggregates from soluble proteins. Supernatants were collected and used for western blotting and mass spectrometry.

Sample Preparation for LC–MS/MS and Label-Free Quantification (LFQ) Data Analysis. Samples were prepared for mass spectrometry using S-Trap micro columns (Protifi) according to the manufacturer’s recommended protocol. Proteins were reduced with 20 mM TCEP at 37 °C for 30 min and alkylated with 20 mM N-ethylmaleimide in the dark for 30 min. A ratio of 1:10 (w:w) trypsin and acetonitrile containing 0.1% FA. Peptides were separated with a linear gradient of 15% to 35% Buffer B in 49 min at 250 nL/min. Twelve fractions were dried under vacuum centrifugation and resuspended in 2% acetonitrile with 0.1% TFA for LC–MS/MS analysis. Labeled peptide samples were injected on a Dionex Ultimate 3000 RSLC (Thermo Fisher Scientific) connected to an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Fisher Scientific). Buffer A consisted of 20 mM ammonium formate pH 8.0 and Buffer B of 100% acetonitrile. Peptides were fractionated using a linear gradient of 1−49% Buffer B over 49 min at 250 nL/min. Twelve fractions were dried under vacuum centrifugation and resuspended in 2% acetonitrile with 0.1% TFA for LC–MS/MS analysis. Labeled peptide samples were injected on a Dionex Ultimate 3000 RSLC (Thermo Fisher Scientific) connected to an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Fisher Scientific). Buffer A consisted of water containing 0.1% FA and Buffer B of 80% acetonitrile containing 0.1% FA. Peptides were separated with a linear gradient of 3−35% Buffer B over 180 min followed by a step from 35−90% Buffer B in 0.5 min at 250 nL/min and held at 90% for 4 min. The gradient was then decreased to 3% Buffer B in 0.5 min at 250 nL/min, and the column was equilibrated for 10 min before the next injection. The scan sequence began with an MS1 spectrum (Orbitrap analysis; resolution 120,000; mass range m/z 375–1500; automatic gain control (AGC) target 4 × 10⁵; maximum injection time 50 ms). MS2 analysis consisted of collision-induced dissociation (CID); AGC 1 × 10⁵; normalized collision energy (NCE) of 30%; maximum injection time of 50 ms; and isolation window of 0.7. Following acquisition of each MS2 spectrum, MS3 precursors were fragmented by high energy collision-induced dissociation (HCD) and analyzed using the Orbitrap (NCE 55%; AGC 5 × 10⁵; maximum injection time 86 ms, resolution was 50,000) and synchronous precursor selection (SPS) was enabled to include 10 MS/MS fragment ions in the FTMS scan.

Mass spectrometry data analysis was performed similarly as described above, but TMT modification on the peptide N-termini or lysine residues was enabled for the 16-plex TMT reagents, and deamidation of asparagine and glutamine was included as variable modification in MaxQuant. TPP data analysis was performed using the TPP packages (https://www.bioconductor.org/packages/release/bioc/html/TPP.html) in the R statistical programming language.

The data were normalized⁰⁵ (Table S3). Proteins that changed significantly in the four replicates between nilotinib and imatinib with a standard deviation below two degrees in the melting temperature were selected as positive hits.
Data Availability. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium9 via the PRIDE partner repository9 with the data set identifier: PXD025020.

Statistical Analysis. The Shapiro–Wilk test was used to check expression data sets for normality, and the Levene test was used for homogeneity of variances. The Mann–Whitney U-test was performed in all the analysis, excluding proteomics and thermal proteome profiling.

ASSOCIATED CONTENT

Supporting Information
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00671.

Figure S1: MALDI-TOF MS spectra; Figure S2: Nilotinib reduces IL-6 and IL-1β secretion; Figure S3: MALDI-TOF MS screening quality control; Figure S4: TPP ratio heatmap; Figure S5: TPP analysis; Figure S6: Nilotinib reduces the pro-inflammatory phenotype; Figure S7: Nilotinib inhibits the pro-inflammatory phenotype in E. coli-activated monocytes; Figure S8: Assessment of TKIs against p38α using surface plasmon resonance (SPR); Figure S9: Differences in the proteome of nilotinib- and imatinib-treated monocytes; Figure S10: Nilotinib and imatinib show different sensitivity in blood malignancies (PDF)

Table S1: List of compounds used in MALDI-TOF MS screen; Table S2: TMT labels; Table S3: Proteins used to normalize TPP data; Table S4: TPP analysis; Table S5: Proteomics ANOVA analysis; Table S6: Proteomics Limma analysis and Gene ontology data; Table S7: MALDI-TOF MS, RTqPCR and ELISA prices for 96 drugs discovery assay and per sample (XLSX)

AUTHOR INFORMATION

Corresponding Authors
José Luis Marín-Rubio – Laboratory for Biological Mass Spectrometry, Biosciences Institute, Newcastle University, Newcastle-upon-Tyne NE2 4HH, UK; orcid.org/0000-0002-7682-0190; Phone: +44 191 2088983; Email: jose.marin-rubio@newcastle.ac.uk
Matthias Trost – Laboratory for Biological Mass Spectrometry, Biosciences Institute, Newcastle University, Newcastle-upon-Tyne NE2 4HH, UK; orcid.org/0000-0002-5732-700X; Phone: +44 191 2087009; Email: matthias.trost@ncl.ac.uk

Authors
Rachel E. Peltier-Heap – Laboratory for Biological Mass Spectrometry, Biosciences Institute, Newcastle University, Newcastle-upon-Tyne NE2 4HH, UK
Maria Emilia Duenas – Laboratory for Biological Mass Spectrometry, Biosciences Institute, Newcastle University, Newcastle-upon-Tyne NE2 4HH, UK
Tian Heunis – Laboratory for Biological Mass Spectrometry, Biosciences Institute, Newcastle University, Newcastle-upon-Tyne NE2 4HH, UK; Sir William Dunn School of Pathology, Oxford OX1 3RE, UK
Abeer Dannoura – Laboratory for Biological Mass Spectrometry, Biosciences Institute, Newcastle University, Newcastle-upon-Tyne NE2 4HH, UK
Joseph Inns – Laboratory for Biological Mass Spectrometry, Biosciences Institute, Newcastle University, Newcastle-upon-Tyne NE2 4HH, UK

Jonathan Scott – Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne NE2 4HH, UK
A. John Simpson – Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne NE2 4HH, UK; Respiratory Medicine Unit, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4LP, UK
Helen J. Blair – Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
Olaf Heidenreich – Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
James M. Allan – Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
Jessica E. Watt – Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK; orcid.org/0000-0001-8926-8617
Mathew P. Martin – Newcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
Barbara Saxty – LifeArc, SBC Open Innovation Campus, Stevenage SG1 2FX, UK

Complete contact information is available at: https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00671

Author Contributions
J.L.M.-R. and R.E.P-H. contributed equally to this work and are co-first authors.

Author Contributions
R.E.P-H. developed the MALDI-TOF MS assay. J.L.M.-R. and R.E.H. performed most of the experiments. M.E.D. performed and analyzed additional MALDI-TOF MS experiments. J.L.M.-R. and T.H. performed LFQ and TMT mass spectrometry-based proteomics. T.H. analyzed TPP experiments. A.D. and J.I. performed additional experiments. J.S. and A.J.S. provided critical feedback and helped shape the research, analysis, and manuscript.

Notes
The authors declare no competing financial interest.

ACKNOWLEDGMENTS
We would like to thank Wezi Sendama, Marie-Hélène Ruchaud-Sparagano, Akshada Gajbhiye, Julien Peltier, and Anetta Hartlova for their technical support and Maria Villamar-Morales for a critical reading of this manuscript. This research was partly funded by a Wellcome Trust Investigator Award (215542/Z/19/Z) and generous start-up funding of Newcastle University to M.T. This research was partly funded by Newcastle Wellcome Translational Partnership to J.L.M.-R., M.E.F., and M.T. R.E.H. was funded by an iCASE studentship by the BBSRC and Bruker Daltonics. M.E.D. is a Marie Skłodowska-Curie Fellow within the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 890296. For the
purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. Professor Simpson is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the authors and not necessarily those of the NIHR, or the Department of Health and Social Care.

**ABBREVIATIONS USED**

AML, acute myeloid leukemia; BET, bromodomain and extra-terminal motif proteins; CAMs, cell adhesion molecules; CML, chronic myeloid leukemia; DAMPs, damage-associated molecular; E50, half maximal effective concentration; ESI, electrospray ionization; FDR, false discovery rate; FDA, Food and Drug Administration; GDSC, genomics of drug sensitivity in cancer; HPLC, high-performance liquid chromatography; HTS, high-throughput screening; IC50, half maximal inhibitory concentration; IL, interleukin; IRAKs, IL-1R-associated kinases; IFN, interferon; JNK, jun N-terminal kinases; LPS, lipopolysaccharides; MAPK family in inflammatory regulation in human pulmonary microvascular endothelial cells stimulated with LPS and IFN-gamma. Immunobiology 2018, 223, 777–785.

**REFERENCES**

(1) Gordon, S.; Taylor, P. R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5, 953–964.

(2) Stuhlmüller, B.; Ungethum, U.; Scholze, S.; Martinez, L.; Backhaus, M.; Kraetsch, H. G.; Kinne, R. W.; Burmester, G. R. Identification of known and novel genes in activated monocytes from patients with rheumatoid arthritis. Arthritis Rheum. 2000, 43, 775–790.

(3) Binder, S.; Luciano, M.; Horejs-Hoeck, J. The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev. 2018, 43, 8–15.

(4) Craver, B. M.; El Alaoui, K.; Scherer, R. M.; Fleischman, A. G. The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies. Cancers 2018, 10, 104.

(5) Hemmati, S.; Haque, T.; Gritsman, K. Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells. Front. Oncol. 2017, 7, 265.

(6) Monlisch, D. A.; Bhatt, S. T.; Schuettelpfla. L. G. The Role of Toll-Like Receptors in Hematopoietic Malignancies. Front. Immunol. 2016, 7, 390.

(7) Kim, E. K.; Choi, E. J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 2010, 1802, 396–405.

(8) Suzuki, T.; Sakata, K.; Mizuno, N.; Palikhe, S.; Yamashita, S.; Hattori, K.; Matsuda, N.; Fattori, Y. Different involvement of the MAPK family in inflammatory regulation in human pulmonary microvascular endothelial cells stimulated with LPS and IFN-gamma. Immunobiology 2018, 223, 777–785.

(9) Mogensen, T. H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 2009, 22, 240–273.

(10) Ingles, J.; Johnson, R. L.; Simeonov, A.; Xia, M.; Zheng, W.; Austin, C. P.; Auld, D. S. High-throughput screening assays for the identification of chemical probes. Nat. Chem. Biol. 2007, 3, 466–479.

(11) Dauli, P. S.; Sandborn, W. J. Next-Generation Therapeutics for Inflammatory Bowel Disease. Curr. Gastroenterol. Rep. 2016, 18, 51.

(12) Li, P.; Zheng, Y.; Chen, X. Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Front. Pharmacol. 2017, 8, 191.

(13) McLaren, D. G.; Shah, V.; Wisniewski, T.; Ghislain, L.; Liu, C.; Zhang, H.; Saldanha, S. A. High-Throughput Mass Spectrometry for Hit Identification: Current Landscape and Future Perspectives. SLAS Discov. 2021, 26, 168–191.

(14) Guittot, K.; Drujon, T.; Burlina, F.; Sagan, S.; Beaufrie-Berrier, S.; Pamlard, O.; Dodd, R. H.; Guilou, C.; Bollbach, G.; Sacko, E.; Guinanvarch, D. A direct label-free MALDI-TOF mass spectrometry based assay for the characterization of inhibitors of protein lysine methyltransferases. Anal. Bioanal. Chem. 2017, 409, 3767–3777.

(15) Heep, R. E.; Hope, A. G.; Pearson, L. A.; Reyskens, K.; McElroy, S. P.; Hastie, C. J.; Porter, D. W.; Arthur, J. S. C.; Gray, D. W.; Tost, M. Identifying Inhibitors of Inflammation: A Novel High-Throughput MALDI-TOF Screening Assay for Salt-Inducible Kinases (SIKs). SLAS Discov. 2017, 22, 1193–1202.

(16) De Cesare, V.; Johnson, C.; Barlow, V.; Hastie, J.; Knebel, A.; Tost, M. The MALDI-TOF E2/E3 Ligase Assay as Universal Tool for Drug Discovery in the Ubiquitin Pathway. Cell Chem. Biol. 2018, 25, 1117–1127.

(17) Dreisewerd, K. Recent methodological advances in MALDI mass spectrometry. Anal. Bioanal. Chem. 2014, 406, 2261–2278.

(18) Chandler, J.; Haslam, C.; Hardy, N.; Leveridge, M.; Marshall, P. A Systematic Investigation of the Best Buffers for Use in Screening by MALDI-Mass Spectrometry. SLAS Discov. 2017, 22, 1262–1269.

(19) Ritorto, M. S.; Ewan, R.; Perez-Oliva, A. B.; Knebel, A.; Buhrlage, S. J.; Wightman, M.; Kelly, S. M.; Wood, N. T.; Virdee, S.; Gray, N. S.; Morrice, N. A.; Alessi, D. R.; Tost, M. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. Nat. Commun. 2014, 5, 4763.

(20) Wang, K. Y.; Chuang, S. A.; Lin, P. C.; Huang, L. S.; Chen, S. H.; Ouarda, S.; Pan, W. H.; Lee, P. Y.; Lin, C. C.; Chen, Y. J. Multiplexed immunoassay: quantitation and profiling of serum biomarkers using magnetic nanoprobes and MALDI-TOF MS. Anal. Chem. 2008, 80, 6159–6167.

(21) Needles, J.; Dantuma, N. P. Fluorescent probes for proteolysis: tools for drug discovery. Nat. Rev. Drug Discov. 2004, 3, 58–69.

(22) Adeghola, S. O.; Sahnan, K.; Warusavitarne, J.; Hart, A.; Tozer, P. Anti-TNF Therapy in Crohn’s Disease. Nat. J. Mol. Sci. 2018, 19, 2244.

(23) Smith, M. J.; Ivanov, D. P.; Weber, R. J. M.; Wingfield, J.; Viant, M. R. Acoustic Mist Ionization Mass Spectrometry for Ultrahigh-Throughput Metabolomics Screening. Anal. Chem. 2021, 93, 9258–9266.

(24) Butcher, E. C. Can cell systems biology rescue drug discovery? Nat. Rev. Drug Discov. 2005, 4, 461–467.

(25) Michelin, E.; Cevenini, L.; Mezzanotte, L.; Coppa, A.; Roda, A. Cell-based assays: fuelling drug discovery. Anal. Bioanal. Chem. 2010, 398, 227–238.

(26) Gerets, H. H.; Dhalluin, S.; Atienza, F. A. Multiplexing cell viability assays. Methods Mol. Biol. 2011, 740, 91–101.

(27) Savitski, M. M.; Reinhard, F. B.; Franken, H.; Werner, T.; Savitski, M. F.; Eberhard, D.; Martinez Molina, D.; Jafari, R.; Dovega, R. B.; Klaeger, S.; Kuster, B.; Nordlund, P.; Bantscheff, M.; Drewe, G. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 2014, 346, 1255784.

(28) Mateus, A.; Kurzawa, N.; Becher, I.; Sridharan, S.; Helm, D.; Stein, F.; Tylps, A.; Savitski, M. M. Thermal proteome profiling for interrogating protein interactions. Mol. Syst. Biol. 2020, 16, No. e9232.

(29) Jarzab, A.; Kurzawa, N.; Hopf, T.; Moerch, M.; Zecha, J.; Leijten, N.; Bian, Y.; Musiol, E.; Maschberger, M.; Stoehr, G.; Becher, I.; Daly, C.; Samaras, P.; Mergner, J.; Spanier, B.; Angelov, A.; Werner, T.; Bantscheff, M.; Wilhelm, M.; Klingenpor, M.; Lemeer,
S.; Liebl, W.; Hahne, H.; Savitski, M. M.; Kuster, B. Meltrone at thermal proteome stability across the tree of life. Nature. Methods 2020, 17, 495–503.

(30) Mateus, A.; Maatta, T. A.; Savitski, M. M. Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes. Proteome Sci. 2016, 15, 13.

(31) Becher, I.; Werner, T.; Doce, C.; Zaal, E. A.; Togel, I.; Khan, C. A.; Rueger, A.; Muelbauer, M.; Salzer, E.; Berkers, C. R.; Fitzpatrick, P. F.; Bantschett, M.; Savitski, M. M. Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat. Nat. Chem. Biol. 2016, 12, 908–910.

(32) Reinhard, F. B.; Eberhard, D.; Werner, T.; Franken, H.; Childs, D.; Doce, C.; Savitski, M. F.; Huber, W.; Bantschett, M.; Savitski, M. M.; Drewes, G. Thermal proteome profiling monitors ligand interactions with cellular membrane proteins. Nature Methods 2015, 12, 1129–1131.

(33) Franken, H.; Mathieson, T.; Childs, D.; Sweetman, G. M.; Werner, T.; Togel, I.; Doce, C.; Gade, S.; Bantschett, M.; Drewes, G.; Reinhard, F. B.; Huber, W.; Savitski, M. M. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat. Protoc. 2015, 10, 1567–1593.

(34) Zinn, N.; Werner, T.; Doce, C.; Mathieson, T.; Boecker, C.; Sweetman, G.; Fufezan, C.; Bantschett, M. Improved Proteomics-Based Drug Mechanism-of-Action Studies Using 16-Plex Isobaric Mass Tags. J. Proteome Res. 2021, 20, 1792–1801.

(35) Miettinen, T. P.; Peltier, J.; Hartlova, A.; Gierlinski, M.; Jansen, V. M.; Trost, M.; Bjorklund, M. Thermal proteome profiling of breast cancer cells reveals protosomal activation by CDK4/6 inhibitor palbociclib. EMBO J. 2018, 37, No. e98359.

(36) De Cesare, V.; Morán, J.; Traynor, R.; Knebel, A.; Ritorto, M. S.; Trost, M.; Maclachlan, H.; Hastie, C. J.; Davies, P. High-throughput matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry-based deubiquitylating enzyme assay for drug discovery. Nat. Protoc. 2020, 15, 4034–4057.

(37) Boshart, H.; Heinzelmann, M. THP-1 cells as a model for human monocytes. Ann. Transl. Med. 2016, 4, 438.

(38) Malik, N.; Vollmer, S.; Nanda, S. K.; Lopez-Pelaez, M.; Prescott, A.; Gray, N.; Cohen, P. Suppression of interferon beta gene assay for drug discovery. Nat. Protoc. 2015, 10, 1567–1593.

(39) Xu, W.; Mo, J.; Oacak, U.; Travis, Z. D.; Enkhjargal, B.; Zhang, T.; Wu, P.; Peng, J.; Li, T.; Zuo, Y.; Shao, A.; Tang, J.; Zhang, J.; Zhan, J.; Bischoff, D.; Luippold, A. H.; Ries, R.; Hehn, J. P.; Winter, M.; Kleiner, C.; Ries, R.; Das, R. J.; Rupasinghe, H. P. V. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol. Cancer 2018, 17, 48.

(40) Newman, A. C.; Scholefield, C. L.; Kemp, A. J.; Newman, M.; McIver, E. G.; Kamal, A.; Wilkinson, S. TBK1 kinase addiction in lung cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib. EMBO J. 2015, 468, 363–372.

(41) Wu, Y.; Mo, J.; Oacak, U.; Travis, Z. D.; Enkhjargal, B.; Zhang, T.; Wu, P.; Peng, J.; Li, T.; Zuo, Y.; Shao, A.; Tang, J.; Zhang, J.; Zhan, J.; Bischoff, D.; Luippold, A. H.; Ries, R.; Hehn, J. P.; Winter, M.; Kleiner, C.; Ries, R.; Das, R. J.; Rupasinghe, H. P. V. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol. Cancer 2018, 17, 48.

(45) Eyers, P. A.; van den, I. P.; Quinlan, R. A.; Goedert, M.; Cohen, P. Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett. 1999, 451, 191–196.

(46) Ma, W.; Lim, W.; Gee, K.; Aucoin, S.; Nandan, D.; Kozlowski, M.; Diaz-Mitoma, F.; Kumar, A. The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J. Biol. Chem. 2001, 276, 13664–13674.

(47) Chen, R. F.; Wang, L.; Cheng, J. T.; Yang, K. D. Induction of IFNalpha or IL-12 depends on differentiation of THP-1 cells in dendge infections without and with antibody enhancement. BMC Infect. Dis. 2012, 12, 340.

(48) Kounalakis, N. S.; Corbett, S. A. Lipopolysaccharide transiently activates THP-1 cell adhesion. J. Surg. Res. 2006, 135, 137–143.

(49) Park, G. S.; Kim, J. H. LPS Up-Regulates ICAM-1 Expression in Breast Cancer Cells by Stimulating a MyD88-BTL2-ERK-Linked Cascade, Which Promotes Adhesion to Monocytes. Mol. Cells 2015, 38, 821–828.

(50) Sasaki, K.; Kantarjian, H.; Jabbour, E.; Ravandi, F.; Takahashi, K.; Konopleva, M.; Borthakur, G.; Garcia-Manero, G.; Wierda, W.; Daver, N.; Jain, P.; Satta, T.; Pierce, S.; Rios, M. B.; Cortes, J. E. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016, 101, e324–e327.

(51) Recher, C. Clinical Implications of inflammation in Acute Myeloid Leukemia. Front. Oncol. 2021, 11, No. 623952.

(52) Kantarjian, H.; Kadia, T.; DiNardo, C.; Daver, N.; Borthakur, G.; Jabbour, E.; Garcia-Manero, G.; Konopleva, M.; Ravandi, F. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021, 11, 41.

(53) Fernandez, S.; Desplat, V.; Villacrecses, A.; Guitart, A. V.; Milipied, N.; Pigneur, A.; Vignon, I.; Pasquet, J. M.; Dumas, P. Y. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How? Int. J. Mol. Sci. 2019, 20, 3429.

(54) Bhullar, K. S.; Lagaron, N. O.; McGowan, E. M.; Parmar, L.; Jha, A.; Hubbard, B. P.; Rupasinghe, H. P. V. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol. Cancer 2018, 17, 48.

(55) Cohen, L. H.; Gusev, A. I. Small molecule analysis by MALDI mass spectrometry. Anal. Bioanal. Chem. 2002, 373, 571–586.

(56) Aichler, M.; Walch, A. MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab. Invest. 2015, 95, 422–431.

(57) Simon, R. P.; Winter, M.; Kleiner, C.; Wehrle, L.; Karnath, M.; Ries, R.; Zeeb, M.; Schnapp, G.; Fiegen, D.; Habe, T. T.; Runge, F.; Bretschneider, T.; Luippold, A. H.; Bischoff, D.; Reindl, W.; Buttner, F. H. MALDI-TOF-Based Affinity Selection Mass Spectrometry for Automated Screening of Protein-Ligand Interactions at High Throughput. SLAS Discov. 2021, 26, 44–47.

(58) Winter, M.; Ries, R.; Kleiner, C.; Bischoff, D.; Luippold, A. H.; Bretschneider, T.; Buttner, F. H. Automated MALDI Target Preparation Concept: Providing Ultra-High-Throughput Mass Spectrometry-Based Screening for Drug Discovery. SLAS Technol. 2019, 24, 209–221.

(59) Winter, M.; Bretschneider, T.; Kleiner, C.; Ries, R.; Hahn, J. P.; Redemann, N.; Luippold, A. H.; Bischoff, D.; Buttner, F. H. Establishing MALDI-TOF as Versatile Drug Discovery Readout to Dissect the PTP1B Enzymatic Reaction. SLAS Discov. 2018, 23, 561–573.

(60) Haslam, C.; Helicar, J.; Dunn, A.; Fuettner, A.; Hardy, N.; Marshall, P.; Pape, R.; Pemberton, M.; Resemannad, A.; Leveridge, M. The Evolution of MALDI-TOF Mass Spectrometry toward Ultra-High-Throughput Screening: 1536-Well Format and Beyond. J. Biomol. Screen. 2016, 21, 176–186.

(61) Heap, R. E.; Segarra-Fas, A.; Blain, A. P.; Findlay, G. M.; Trost, M. Profiling embryonic stem cell differentiation by MALDI TOF
mass spectrometry: development of a reproducible and robust sample preparation workflow. Analyst 2019, 144, 6371–6381.
(62) Kriegsmann, M.; Seeley, E. H.; Schwarting, A.; Kriegsmann, J.; Otto, M.; Thabe, H.; Dierkes, B.; Biehl, C.; Sack, U.; Wellmann, A.; Kahaly, G. J.; Schwamborn, K.; Caprioli, R. M. MALDI MS imaging as a powerful tool for investigating synovial tissue. Scand. J. Rheumatol. 2012, 41, 305–309.
(63) Zhang, F.; Xu, C.; Ning, L.; Hu, F.; Shan, G.; Chen, H.; Yang, M.; Chen, W.; Yu, J.; Xu, G. Exploration of Serum Proteome Profiling and Diagnostic Model That Differentiate Crohn’s Disease and Intestinal Tuberculosis. PLoS One 2016, 11, No. e0167109.
(64) Holzlechner, M.; Strasser, K.; Zareva, E.; Steinhauser, L.; Birnleitner, H.; Beer, A.; Bergmann, M.; Oehler, R.; Marchetti-Deschmann, M. In Situ Characterization of Tissue-Resident Immune Cells by MALDI Mass Spectrometry Imaging. J. Proteome Res. 2017, 16, 65–76.
(65) Jabbour, E.; Kantarjian, H.; Cortes, J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin. Lymphoma Myeloma Leuk. 2015, 15, 323–334.
(66) Guo, K.; Bu, X.; Yang, C.; Cao, X.; Bian, H.; Zhu, Q.; Zhu, J.; Zhang, D. Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis. Front. Immunol. 2018, 9, 3133.
(67) Akashi, N.; Matsumoto, I.; Tanaka, Y.; Inoue, A.; Yamamoto, K.; Umeda, N.; Tanaka, Y.; Hayashi, T.; Goto, D.; Ito, S.; Sekiguchi, K.; Sumida, T. Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis. Mod. Rheumatol. 2011, 21, 267–275.
(68) Ozanne, J.; Prescott, A. R.; Clark, K. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophage functions by inhibiting the salt-inducible kinases. Biochem. J. 2015, 465, 271–279.
(69) Griffin, J. D.; Rambaldi, A.; Vellenga, E.; Young, D. C.; Ostapovicz, D.; Cannistra, S. A. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood 1987, 70, 1218–1221.
(70) Yang, R. B.; Mark, M. R.; Gray, A.; Huang, A.; Xie, M. H.; Zhang, M.; Goddard, A.; Wood, W. I.; Gurney, A. L.; Godowski, P. J. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998, 395, 284–288.
(71) Arthur, J. S.; Ley, S. C. Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol. 2013, 13, 679–692.
(72) Canovas, B.; Nebreda, A. R. Diversity and versatility of p38 MAPK insert.
(73) Liang, X.; Liu, X.; Wang, B.; Zou, F.; Wang, A.; Qi, S.; Chen, X.; Zhao, Z.; Wang, W.; Qi, Z.; Lv, F.; Hu, Z.; Wang, L.; Zhang, S.; Liu, Q.; Liu, J. Discovery of 2-(3-Amino-4-methylphenyl)aminomethyl-N-(2-methyl-5-(3-trifluoromethyl)benzamido)phenyl)-4-(methylamino)-pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia. J. Med. Chem. 2016, 59, 1984–2004.
(74) Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2011, 29, 1046–1051.
(75) Li, Y. Y.; An, J.; Jones, S. J. A computational approach to finding novel targets for existing drugs. PLoS Comput. Biol. 2011, 7, No. e1002139.
(76) Kitagawa, D.; Yokota, K.; Gouda, M.; Narumi, Y.; Ohmoto, H.; Nishiwaki, E.; Akita, K.; Kirii, Y. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 2013, 18, 110–122.
(77) Beenstock, J.; Ben-Yehuda, S.; Melamed, D.; Admon, A.; Livnah, O.; Ahn, N. G.; Engelberg, D. The p38beta mitogen-activated protein kinase possesses an intrinsic autophosphorylation activity, generated by a short region composed of the alpha-G helix and MAPK insert. J. Biol. Chem. 2014, 289, 23546–23556.
(96) Tyanova, S.; Temu, T.; Sinitsyn, P.; Carlson, A.; Hein, M. Y.; Geiger, T.; Mann, M.; Cox, J. The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods* 2016, 13, 731–740.

(97) Huang da, W.; Sherman, B. T.; Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* 2009, 4, 44–57.

(98) Deutsch, E. W.; Csordas, A.; Sun, Z.; Jarnuczak, A.; Perez-Riverol, Y.; Ternent, T.; Campbell, D. S.; Bernal-Llinares, M.; Okuda, S.; Kawano, S.; Moritz, R. L.; Carver, J. J.; Wang, M.; Ishihama, Y.; Bandeira, N.; Hermjakob, H.; Vizcaíno, J. A. The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition. *Nucleic Acids Res.* 2017, 45, D1100–D1106.

(99) Perez-Riverol, Y.; Csordas, A.; Bai, J.; Bernal-Llinares, M.; Hewapathirana, S.; Kundu, D. J.; Inuganti, A.; Griss, J.; Mayer, G.; Eisenacher, M.; Perez, E.; Uszkoreit, J.; Pfeuffer, J.; Sachsenberg, T.; Yilmaz, S.; Tiwary, S.; Cox, J.; Audain, E.; Walzer, M.; Jarnuczak, A. F.; Ternent, T.; Brazma, A.; Vizcaíno, J. A. The PRIDE database and related tools and resources in 2019: improving support for quantification data. *Nucleic Acids Res.* 2019, 47, D442–D450.